BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Nivolumab: trial readouts and FDA decisions
6 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 7 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Bristol-Myers Squibb, BicycleTx Limited, Exelixis, TaiRx, Inc., IDEAYA Biosciences, Sanofi, Corcept Therapeutics, Arcus Biosciences, Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-15 est. | P3 | Exelixis EXEL | NCT05678673 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | Non-Clear Cell Renal Cell Carcinoma | active not recruiting | 317 |
| 2026-12-31 est. | P1/P2 | BicycleTx Limited | NCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | Advanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer; Ovarian Cancer | active not recruiting | 288 |
| 2026-12-31 est. | P2 | TaiRx, Inc. | NCT05257590 CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma; Advanced Cancer | recruiting | 95 |
| 2027-01-15 est. | P2/P3 | IDEAYA Biosciences IDYA | NCT05987332 IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | Metastatic Uveal Melanoma | active not recruiting | 420 |
| 2027-01-19 est. | P1/P2 | Sanofi SNY | NCT05584670 A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | Solid Tumor | recruiting | 542 |
| 2027-02-05 est. | P2 | Bristol-Myers Squibb BMY | NCT06946797 A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Un | Non-Small Cell Lung Cancer | active not recruiting | 76 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-09-30 est. | P1/P2 | Bristol-Myers Squibb BMY | NCT05888831 A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors | Advanced Solid Tumors | active not recruiting | 100 |
| 2026-09 est. | P1/P2 | Corcept Therapeutics CORT | NCT07276373 Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies | Neoplasms | recruiting | 50 |
| 2026-08-28 | P3 | Arcus Biosciences, Inc. RCUS | NCT05568095 A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That C | Advanced Upper Gastrointestinal Tract Adenocarcinoma | completed | 1040 |
| 2026-08 est. | P1/P2 | BicycleTx Limited | NCT05163041 Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression | Advanced Solid Tumor | active not recruiting | 200 |
| 2026-07-09 | P3 | Bristol-Myers Squibb BMY | NCT04039607 A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | completed | 732 |
| 2026-07 est. | P3 | HUYABIO International, LLC. | NCT04674683 Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma | Unresectable or Metastatic Melanoma; Progressive Brain Metastasis | active not recruiting | 450 |
| 2026-05-27 | P3 | Bristol-Myers Squibb BMY | NCT03383458 A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Hepatocellular Carcinoma; Liver Cancer | active not recruiting | 545 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.